Baker, Brook K., "Settlement of India/EU WTO dispute re seizures of in-transit medicines: why the proposed EU border regulation isn't good enough" (2012) (1) continued coverage of alleged patent and supplemental protection certificate infringement claims that can be based on fictional patent status under national law; the addition of utility models; and continued coverage of design rights and civil trademark infringement matters that are more appropriately addressed in ordinary court proceedings; (2) inappropriate application of the law of the in-transit country instead of the law of the importing country when assessing an IP infringement claim; (3) unclear directives to "consider" the risk of diversion to EU markets with no explicit prohibition against seizing in-transit medicines in the absence of such a showing and without requirement of clear and convincing evidence of an imminent diversion by an identified party; (4) insufficient opportunities to be heard for declarants and holders of goods; and (5) insufficient remedies for declarants and holders of goods and for purchasers and consumers who are proximately harmed by unsuccessful border applications.
India has assured the EU that it will not request the establishment of a dispute settlement panel at the WTO. However, India retains the option to revive the dispute if the EU does not abide by the core principles agreed to in the Understanding. 10 This Understanding between the EU and India does not directly impact the parallel WTO dispute filed by Brazil, but as a practical matter, Brazil"s dispute is likely to be suspended pending final enactment of the new Regulation. The question arises whether India is correct that the Proposed Border Regulation in its current form will not adequately resolve the risk of interception in Europe of medicines lawfully manufactured and exported from India and destined for lawful import and consumption in a non-EU country. This analysis concludes that multiple weaknesses remain, including:
1. continued coverage of alleged patent and supplemental protection certificate infringement claims that can be based on fictional patent status under national law; the addition of utility models; and continued coverage of design rights and civil trademark infringement matters that are more appropriately addressed in ordinary court proceedings; 2. inappropriate application of the law of the in-transit country instead of the law of the importing country when assessing an IP infringement claim; 3. directives to "consider" the risk of diversion to EU markets with no explicit prohibition against seizing in-transit medicines in the absence of such a showing and without requirement of clear and convincing evidence of an imminent diversion by an identified party; 4. insufficient opportunities to be heard for declarants and holders of goods; and 5. insufficient remedies for declarants and holders of goods and for purchasers and consumers who are proximately harmed by unsuccessful border applications.
Unless these public health weaknesses are addressed, India"s WTO complaint should not be withdrawn. Abbott, supra note 12, at 44-45. The territoriality criticism is based on the premise that IPrelated acts done outside a nation"s territory do not violate the territorial rights in force within national borders and that medicines temporarily in-transit do not involve any prohibited "use" of the patent (making, using, offering for sale, selling, or importing for these purposes) within a country"s territorial market. goods coming from a non-member State which are imitations of goods protected in the European Union by a trade mark right or copies of goods protected in the European Union by copyright, a related right or a design cannot be classified as "counterfeit goods" or "pirated goods" within the meaning of those regulations merely on the basis of the fact that they are brought into the customs territory of the European Union under a suspensive procedure; -those goods may, on the other hand, infringe the right in question and therefore be classified as "counterfeit goods" or "pirated goods" where it is proven that they are intended to be put on sale in the European Union, such proof being provided, inter alia, where it turns that the goods have been sold to a customer in the European Union or offered for sale or advertised to consumers in the European Union, or where it is apparent from documents or correspondence concerning the goods that their diversion to European Union consumers is envisaged; -in order that the authority competent to take a substantive decision may profitably examine whether such proof and the other elements constituting an infringement of the intellectual property right relied upon exist, the customs authority to which an application for action is made must, as soon as there are indications before it giving grounds for suspecting that such an infringement exists, suspend the release of or detain those goods; and -those indications may include, inter alia, the fact that the destination of the goods is not declared whereas the suspensive procedure requested requires such a declaration, the lack of precise or reliable information as to the identity or address of the manufacturer or consignor of the goods, a lack of cooperation with the customs authorities or the discovery of documents or correspondence concerning the goods in question suggesting that there is liable to be a diversion of those goods to European Union consumers. 29 Id. at ¶ 62. For further legal clarity and in order to protect the interests of legitimate traders from possible abuse of the border enforcement provisions, it is appropriate to modify the timelines for detaining goods suspected of infringing an intellectual property right, the conditions in which information about consignments is to be passed on to right-holders by customs authorities, the conditions for applying the procedure allowing for destruction of the goods under customs control for suspected infringements of intellectual property rights other than for counterfeit and pirated goods and to introduce a provision allowing the holder of the goods to express his/her views before the customs administration takes a decision which would adversely affect him/her. Collectively these procedural protections, though improvements, do not totally ameliorate the risk of abusive applications for detention of goods nor remedy the harm not only to declarants and holders of the goods but also to purchasers of essential lifesaving medicines and their ultimate consumers who may suffer adverse health effects because of the interception of legitimate in-transit medicines.
34 Proposed Border Regulation, supra note 6 at Recital No. 17:
Under the "Declaration on the TRIPS Agreement and Public Health" adopted by the Doha WTO Ministerial Conference on 14 November 2001, the TRIPS Agreement can and should be interpreted and implemented in a manner supportive of WTO Members' right to protect public health and, in particular, to promote Problems with the Proposed Border Regulation include:
1. The proposed regulation continues coverage of patents, supplementary protection certificates for medicinal products (patent extensions), design rights, and civil trademark infringements, and thus continues to threaten access to medicines.
37
In fact, the proposal extends border measures to entirely new intellectual property rights, including trade names, topographies of semiconductor products, utility models, and devices to circumvent technological measures, as well as any exclusive intellectual access to medicines for all. …" It is important to note that this recital is preambular and imposes no direct obligation on an EU Member State.
35 Id. at Recital 11; Art. 20.
Where goods suspected of infringing intellectual property rights are no counterfeit or pirated goods, it may be difficult to determine upon mere visual examination by customs authorities whether an intellectual property right might be infringed. It is therefore appropriate to provide that proceedings should be initiated, unless the parties concerned, namely the holder of the goods and the right-holder, agree to abandon the goods for destruction. It should be for the competent authorities dealing with such proceedings to determine whether an intellectual property right has been infringed and to take appropriate decisions concerning the infringements of intellectual property rights concerned. 36 See, e.g., Thomas Jaeger, Henning Grosse Ruse-Khan, Josef Drexl & Reto M. Hilty, For the purposes of this Agreement: (a) "counterfeit trademark goods" shall mean any goods, including packaging, bearing without authorization a trademark which is identical to the trademark validly registered in respect of such goods, or which cannot be distinguished in its essential aspects from such a trademark, and which thereby infringes the rights of the owner of the trademark in question under the law of the country of importation (emphasis added); (b) "pirated copyright goods" shall mean any goods which are copies made without the consent of the right holder or person duly authorized by the right holder in the country of production and which are made directly or indirectly from an article where the making of that copy would have constituted an infringement of a copyright or a related right under the law of the country of importation. TRIPS Article 61, in relevant part reads:
Statement of the Max Planck institute for Intellectual Property, Competition and Tax Law on the Review of EU Legislation on Customs Enforcement of Intellectual Property Rights
Members shall provide for criminal procedures and penalties to be applied at least in cases of willful trademark counterfeiting or copyright piracy on a commercial scale. Remedies available shall include imprisonment and/or monetary fines sufficient to provide a deterrent, consistently with the level of penalties applied for crimes of a corresponding gravity. In appropriate cases, remedies available shall also include the seizure, forfeiture and destruction of the infringing goods and of any materials and implements the predominant use of which has been in the commission of the offence. (Emphasis added.) 40 Some health officials are now arguing that it may be desirable to encourage generic equivalents to have the same appearance or trade (size, shape, and color of the medicine) so as to promote generic substitution and reduce prescription errors by pharmacists, to avoid patient confusion, and to enhance patient adherence. Jeremy A. whether an intellectual property right has been infringed under national law will be conducted with reference to the criteria used to establish whether goods produced in that Member State infringe intellectual property rights (emphasis added)." The use of the phrase "use of those goods" versus "goods produced" would not seem to directly undermine the continuing viability of the manufacturing fiction under national law. For example, Article 28 of the TRIPS Agreement covers both "manufacturing" (production) and "use." 43 Moreover, the Proposed Border Regulation is clear that 41 Proposed Border Measure, supra note 6, Art. 2(7)(a). Although this language is somewhat confusing, its main import is that the law of individual EU Member States will continue to apply. 42 Id. Art. 3
Applicable Law: … the law of the Member State where the goods are found in one of the situations referred to in Article 1(1) shall apply for the purpose of determining whether the use of those goods gives rise to suspicion of infringement of an intellectual property right or has infringed an intellectual property right (emphasis added). 43 TRIPS, supra note 2119:
A patent shall confer on its owner the following exclusive rights: (a) where the subject matter of a patent is a product, to prevent third parties not having the owner"s consent from the acts of: making, using, offering for sale, selling, or importing for
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it is not intended to affect in any way the laws of Member States. 44 Accordingly, if a country maintains the manufacturing fiction with respect to assessing the patent or supplementary protection status of a medicine, as the Netherlands and other European countries clearly do, 45 then an in-transit generic medicine could still be seized, adjudicated as an infringement, and thus destroyed, even if it was lawfully produced in the country of manufacture and destined for legal use in the final country of import. This fictive, non-territorial application of domestic law to transit goods is in direct violation of Articles 52 46 and 51, footnote 14 47 of the TRIPS Agreement, which requires application of "the law of the importing country" when assessing whether an intellectual property right at the border is violated or whether a good is a trademark counterfeit. There is no justification for applying fictive domestic IP law to goods that are not "used" so as to violate IP rights within the territorial market of the transit country. Applying such fictive rights, in essence becomes an extra-territorial application of purely domestic IP law and IP status to goods that are destined for commercialization or other use within that territory. To apply such fictive territorial rules could disrupt broad swathes of international trade using the most efficient trade routes as permitted by GATT. Dangerously, there is no reason that such fictive territoriality could not be extended with respect to other territorial regimes including labor rights, environmental rights, packaging/disclosure requirements, licensure, etc. Finally, any continued use of the manufacturing fiction should now be decisively illegal pursuant to the recent judgment of the European Court of Justice.
48 these purposes that product; (b) where the subject matter of a patent is a process, to prevent third parties not having the owner"s consent from the act of using the process, and from the acts of: using, offering for sale, selling, or importing for these purposes at least the product obtained directly by that process. 44 Proposed Border Measure, supra note 6, Art. Court of Justice"s ruling is undesirably weak with respect to authorizing temporary detention pending final adjudication of planned diversion directed at EU consumers. Accordingly, the proposed "evidence of diversion" provision justifying even temporary detention would be substantially strengthened if it were incorporated into the actual text of the regulation itself and if it were to say: "There may be no determination of prima facie suspicion of or violation of a covered intellectual property right in the absence of compelling evidence showing a substantial likelihood of imminent diversion of the challenged goods by an identified party onto the market of the European Union."
49 Proposed Border Measure, supra note 6, Recital 17.
In particular with regard to medicines the passage of which across this territory of the European Union, with or without transshipment, warehousing, breaking bulk, or changes in the mode or means of transport, is only a portion of a complete journey beginning and terminating beyond the territory of the Union, customs authorities should, when assessing a risk of infringement of intellectual property rights, take account of any substantial likelihood of diversion of these goods onto the market of the Union. 50 See supra notes 27-33.
4. The time period for declarants or the holder of goods to respond to detention of suspect goods is too short. Temporary suspension of the release of goods or their detention can be pursued ex parte either by an application of the right-holder or other identified surrogate using Articles 4-6 or by unilateral ex officio action of customs authorities, who thereafter must request the right holder to initiate an application, Article 17. In either event, customs authorities are required to communicate their intentions to the declarant or, in the case of detention, the holder of the goods after the fact, and only then is the declarant or holder "given the opportunity to express his/her views within three working days."
51
Upon granting an application, the competent customs department must suspend the release of the goods or detain them and must promptly notify both the holder of the decision (the right holder) and the declarant or holder of the goods of its decision.
52
Although these notice and opportunity to be heard provisions are an improvement over BMR 1383/2003, the three-day time period granted to declarants and holders of the goods is insufficient to give them fair opportunity to amass evidence concerning the lawful IP status of the goods in issue and to confirm the ultimate destination of in-transit goods outside the EU. Declarants and holders of goods should be given at least 10 days for such a showing and there should be additional provisions allowing for a further extension upon proper motivation. by the customs authority. Admittedly, the goods will be detained, pursuant to a granted application, for only a limited period of time -10 days -unless proceedings are promptly initiated, but goods thereafter can ordinarily be detained until the court proceedings have ended, a time period that can last months or even years. 54 There are procedures for release of goods upon payment of adequate security, and there are eventual remedies for applications and proceedings where it is determined that IP rights have not been violated, but these partial remedies do not always compensate holders of the goods for lost commercial opportunities and disruptions of their business, nor do they provide remedies for intended purchasers and ultimate consumers whose needs for life-saving and healthenhancing medicines have been frustrated. Buyers, including government purchasers might have to use special and higher cost procurement methods to get emergency supplies. If they are fiscally unable to do so, or if suppliers cannot meet their needs immediately because of orders from other customers, public health programs and the immediate medical needs of patients might not be met. At present, there are no remedies for such purchasers or consumers, nor even are there confirmed remedies for declarants or holders of goods unless, and only to the extent that, the law of the country in question so provides. 55 The Proposed Border Regulation should be amended to provide much more certain and robust remedies for declarants and holders of goods and for purchasers and customers who may have suffered harm as a proximate result of right-holders" unsuccessful actions under the regulation.
54 This ten-day period can be extended another ten days upon application except in the case of perishable goods. Id. at Art. 20.4. There are provisions for the declarant or holder of the goods to seek their release from detention, but only if adequate security has been posted, no precautionary measures (preliminary injunctions) have been entered, and all customs formalities completed; Art. 21.1. 55 Id. at Art. 26:
Where a procedure duly initiated pursuant to this Regulation is discontinued owing to an act or omission on the part of the holder of the decision granting the application or where the goods in question are subsequently found not to infringe an intellectual property right, the holder of the decision granting the application shall be liable towards the persons involved in a situation referred to in Article 1(1) in accordance with the legislation of the Member State where the goods were found.
WWW.WCL.AMERICAN.EDU/PIJIP

IV. CONCLUSION
A better regulation would have excluded coverage of patents, supplementary protection certificates, utility models, design rights, and civil trademark violations and/or specifically prevented application of a domestic manufacturing or use fiction with respect to in-transit goods. It would have much more directly addressed the Doha Declaration and clarified that no customs action should be undertaken with respect to in-transit generic medicines lawfully produced in the country of origin and lawfully imported into the country of use, unless there is concrete and compelling evidence of imminent diversion of the goods into the European market by an identified party. Declarants and holders of goods should be given more meaningful opportunities to object to detention and seizure of their goods and to oppose applications by right holders. And, the provisions for remedies when right holders" applications are unsuccessful should be expanded both for declarants/holders-of-goods and ultimate purchasers/consumers whose interests have been proximately harmed by the wrongful detention and/or destruction of goods.
Instead, the EC has attempted to strengthen the enforcement rights of IP right holders and has once again passed the buck to country-specific IP legislative standards and enforcement criteria. These country specific standards and criteria, including the manufacturing/domestic-use fiction, may once again run afoul of fundamental precepts of intellectual property law, the TRIPS Agreement and GATT, and public health needs enshrined in the Doha Declaration and in other binding human rights instruments. Europe has treated its reform obligations primarily as an exercise in balancing expanded intellectual property protections against greater due process rights, without addressing the most fundamental defects in the BMR 1383/2003 regime, a defect that has also been identified by the European Court of Justice. Accordingly, European parliamentarians should reject the Proposed Border Regulation in its current form as should India and Brazil with respect to their suspended WTO complaints.
